Ovarian cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 8, 2008, Pages 766-794

  Morgan Jr , Robert J ^a   Alvarez, Ronald D ^a   Armstrong, Deborah K ^a   Boston, Barry ^a   Chen, Lee May ^a   Copeland, Larry ^a   Fowler, Jeff ^a   Gaffney, David K ^a   Gershenson, David ^a   Greer, Benjamin E ^a   Grigsby, Perry W ^a   Havrilesky, Laura J ^a   Johnston, Carolyn ^a   Lancaster, Johnathan M ^a   Lele, Shashikant ^a   Matulonis, Ursula ^a   O'Malley, David ^a   Ozols, Robert F ^a   Remmenga, Steven W ^a   Sabbatini, Paul ^a   Schink, Julian ^a   Teng, Nelson ^a   more..

^a NONE

Author keywords

BRCA genotypes; CA 125; Carboplatin; Chemotherapy; Cisplatin; Epithelial carcinoma; Gynecologic malignancy; NCCN Clinical Practice Guidelines; Ovarian cancer; Staging; Surgery; Taxane; Treatment guidelines

Indexed keywords

ALTRETAMINE; ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LETROZOLE; LEUPRORELIN; MELPHALAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PLATINUM COMPLEX; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ABDOMINAL HYSTERECTOMY; ABDOMINAL PAIN; ADJUVANT THERAPY; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CATHETER COMPLICATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; DEHYDRATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSGERMINOMA; ENDOMETRIAL STROMAL TUMOR; FAMILY HISTORY; FATIGUE; GERM CELL TUMOR; GRANULOSA CELL TUMOR; HUMAN; INFECTION; LAPAROTOMY; LEUKOPENIA; MIXED MULLERIAN TUMOR; MULTIPLE CYCLE TREATMENT; NAUSEA; NEEDLE BIOPSY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PERITONEAL BIOPSY; PRACTICE GUIDELINE; SALPINGOOOPHORECTOMY; SECOND LOOK SURGERY; SENSORY NEUROPATHY; SURVIVAL RATE; AGED; CARCINOSARCOMA; FEMALE; MIDDLE AGED; NEOPLASM; OVARY TUMOR; RISK FACTOR;

AGED, 80 AND OVER; CARCINOSARCOMA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 53049095230     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0058     Document Type: Article

References (81)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Ozols RF, Rubin SC, Thomas G, et al. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:919-922.
3. Goff BA, Mandel L, Drescher CW, et al. Development of an ovarian cancer symptom index. Cancer 2007;109:221-227.
4. Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005;105:35-41.
5. du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16(Suppl 8):vIii7-viii12.
6. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-1427.
7. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:1-7.
8. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Oncol 2007;25:2873-2883.
9. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:77-85.
10. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction ffor advanced ovarian carcinoma. N Engl J Med 2004;351: 2489-2497.
11. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking ssurgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-634.
12. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med 1990;322:1021-1027.*
13. Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
14. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol 2006;24:988-994.
15. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200.
16. Vasey PA, Jayson GC, Gordon A, etal. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-1691.
17. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
18. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432-439.
19. Markman M. Management of ovarian cancer. An impressive history of improvement in survival and quality of life. Oncology (Williston Park) 2006;20:347-354; discussion 354, 357-358, 364 passim.
20. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2006;100: 27-32.
21. Gore M, du Bois A, Vergote I. Intraperitoneal chemotherapy in ovarian cancer remains experimental. J Clin Oncol 2006;24:4528-4530.
22. Armstrong DK, Brady MF. Intraperitoneal therapy for ovarian cancer: A treatment ready for prime time. J Clin Oncol 2006;24:4531-4533.
23. Ozols RF, Bookman MA, du Bois A, et al. Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol 2006;103:1-6.
24. Möbus V, Wandt H, Frickhofen N, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: Intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol 2007;25:4187-4193.
25. Papadimitriou C, Dafni U, Anagnostopoulos A, et al. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: Results of a single-institution randomized trial. Bone Marrow Transplant 2008;41:547-554.
26. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465.
27. Spriggs DR, Brady MF, Vaccarello L, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007;25:4466-4471.
28. Thomas GM. Radiotherapy in early ovarian cancer. Gynecol Oncol 1994;55(Suppl):S73-79.
29. Sorbe B. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 2003;13:278-286.
30. Tebes SJ, Sayer RA, Palmer JM, et al. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2007;106:482-487.
31. Hatch KD, Beecham JB, Blessing JA, et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 1991;68: 269-271.
32. van der Velden J, Gitsch G, Wain GV, et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995;5:301-305.
33. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-192.
34. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-393.
35. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/ AGO-OVAR-2.2 trial. Lancet 2003;361:2099-2106.
36. Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer 2005;15:18-22.
37. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 200;24:4699-4707.
38. Ferrandina C, Ludovisi M, De Vincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: A phase II study. Ann Oncol 2007;18:1348-1353.
39. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-153.
40. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan vs paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193.
41. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′, 2′ -difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-1533.
42. Rothenberg ML, Liu PY, Wilczynski S, et al. Phase II trial of vinorelbine for relapsed ovarian cancer: A Southwest Oncology Group study. Gynecol Oncol 2004;95:506-512.
43. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1996;14:2546-2551.
44. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15:987-993.
45. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second line therapy for platinum resistant (PLATR) and platinum sensitive (PLATS) ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-410.
46. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007;14:195-208.
47. Alberts DS, Jiang C, Liu PY, et al. Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. Int J Gynecol Cancer 2004;14:224-228.
48. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously-treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1992;10:243-248.
49. Monk BJ, Choi DC, Pugmire G, et al. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96:902-905.
50. Bidus MA, Webb JC, Seidman JD, et al. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 2006;102:5-7.
51. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. Cancer 2006;107:83-89.
52. Burger RA, Sill MW, Monk, BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007;25:5165-5171.
53. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-5186.
54. Wolf JK, Bodurka DC, Verschraegen C, et al. A phase II trial of oral capecitabine in patients with platinum - and taxane-refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 2006;102: 468-474.
55. Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther 2006;6:43-47.
56. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004;66:112-117.
57. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8:2233-2239.
58. del Carmen MG, Fuller AF, Matulonis U, et al. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 2003;91:596-602.
59. Gordon MS, Marei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-4332.
60. Corn BW, Lanciano RM, Boente M, et al. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer 1994;74:2979-2983.
61. Barakat RR, Benjamin I, Lewis JL, et al. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 1995;59:390-393.
62. Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990;65:578-585.
63. Leake JF, Currie JL, Rosenshein NB, et al. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992;47:150-158.
64. Barnhill DR, Kurman RJ, Brady MF, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: A Gynecologic Oncology Group study. J Clin Oncol 1995; 13:2752-2756.
65. Sutton GP, Bundy BN, Omura GA, et al. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991; 41:230-233.
66. Kennedy AW, Hart WR. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors): A long-term followup study, including patients with microinvasion; lymph node metastasis, and transformation to invasive serous carcinoma. Cancer 1996;78: 278-286.
67. Ayhan A, Celik H, Taskiran C, et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol 2003;24:223-232.
68. Zanetta G, Bonazzi C, Cantu M, et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015-1020.
69. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
70. Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 2005;97:489-496.
71. Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. J Clin Oncol 1994;12:701-706.
72. Gershenson DM, Morris M, Cangir A, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990;8:715-720.
73. Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: A trial of the Gynecologic Oncology Group. Gynecol Oncol 2004; 95:496-499.
74. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005;23:6549-6555.
75. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998;16:2500-2504.
76. Hinton S, Catalano P, Einhom LH, et al. Phase Il study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002;20: 1859-1863.
77. Nichols CR, Roth BJ, Loehrer PJ, et al. Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 1994;21(5 Suppl 12): 102-108.
78. Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 2003; 97:1869-1875.
79. Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group study (a final report). Cancer 1985;56:243-248.
80. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003;21:1180-1189.
81. Schneider DT, Calaminus G, Wessalowski R, et al. Ovarian sex cordstromal tumors in children and adolescents. J Clin Oncol 2003;21: 2357-2363.